Breath Biopsy Testing Market Report 2024

This Breath Biopsy Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The breath biopsy testing market size has grown strongly in recent years. It will grow from $2.96 billion in 2023 to $3.18 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be attributed to supportive government programs, a shift towards non-invasive diagnostics, increasing consumer awareness of preventive healthcare, rising use in oncology research, and expanding applications in metabolic disorders.

The breath biopsy testing market size is expected to see strong growth in the next few years. It will grow to $4.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during the forecast period can be attributed to the increasing incidence of respiratory diseases, greater awareness of early disease detection, expansion of clinical research and trials, a rising geriatric population, and the growing prevalence of infectious diseases. Key trends include advancements in breath analysis technology, increased demand for personalized medicine, investments in healthcare infrastructure, collaborations between diagnostic companies and hospitals, and the adoption of AI and data analytics.

The increasing prevalence of respiratory diseases is projected to drive growth in the breath biopsy testing market. Respiratory diseases, which affect the lungs and airways and impair breathing efficiency, are becoming more common due to rising environmental pollution, higher smoking rates, and the growing incidence of chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). Breath biopsy testing provides a non-invasive, rapid, and potentially more accurate method for detecting biomarkers linked to these conditions, thereby enhancing early diagnosis and management. For example, in November 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported approximately 8,331 cases of tuberculosis in the United States for 2022, representing a 5.9% increase from 2021. The incidence rate rose to 2.5 cases per 100,000 people, marking a 5.5% increase compared to the previous year. This rising prevalence of respiratory diseases is expected to propel the growth of the breath biopsy testing market.

Leading companies in the breath biopsy testing market are focusing on developing advanced products, such as breath analyzers, to detect asthma. Breath analyzers are diagnostic devices designed to detect and measure specific compounds in a person's breath to identify medical conditions or assess health status. For instance, in May 2023, GenWorks, an India-based healthcare solutions provider, launched the FenomPro breath analyzer. This device features rapid FeNO testing, delivering results in just 28 seconds. It is designed for ease of use in clinical settings, providing accurate assessments for diagnosing, screening, and monitoring asthma. The FenomPro breath analyzer is equipped with a rechargeable battery for portability, a user-friendly interface, and efficiently determines the need for treatment or inhaler prescriptions.

In November 2023, Syantra Inc., a Canada-based liquid biopsy platform and innovation company, partnered with Limmi to advance the AI-powered RNA-based early cancer detection liquid biopsy program. This collaboration enhances Syantra's capabilities by incorporating a scalable AI-powered liquid biopsy platform from Limmi, which generates novel insights from clinical data and improves the ability to detect multiple cancers at early stages. Limmi is a US-based technology company.

Major companies operating in the breath biopsy testing market are Drägerwerk AG & Co. KGaA, Intoximeters Inc., Owlstone Medical Ltd., SKC Inc, Lifeloc Technologies Inc., Alcolizer Pty Ltd., Breathomix, Aerocrine AB, Bedfont Scientific Ltd., AK GlobalTech Corp., Alveo Technologies Inc., Andatech Pty Ltd., BACtrack, Biosensia Ltd., Ionicon, Ketonix AB, Lion Laboratories Limited, Menssana Research Inc., Microplex Inc., Quest Products Inc., Rapid Biosensor Systems Ltd., RoboScientific Ltd., Spirosure.

North America was the largest region in the breath biopsy testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breath biopsy testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breath biopsy testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Breath biopsy testing is a non-invasive diagnostic technique that examines chemical compounds in a person’s breath to detect and diagnose diseases. This method relies on the principle that specific diseases, metabolic conditions, and physiological states release unique chemical markers or volatile organic compounds (VOCs) that can be identified in exhaled breath.

The main types of breath biopsy testing include volatile organic compound analyzers, breath biopsy kits, breath samplers, and other related tools. Volatile organic compound (VOC) analyzers are instruments designed to detect and measure the concentration of VOCs in the air. These analyzers use various technologies such as fuel cell technology, semiconductor sensors, and infrared (IR) spectroscopy. They are used in hospitals, clinics, diagnostic laboratories, and other settings.

The breath biopsy testing market research report is one of a series of new reports that provides breath biopsy testing market statistics, including breath biopsy testing industry global market size, regional shares, competitors with a breath biopsy testing market share, detailed breath biopsy testing market segments, market trends and opportunities, and any further data you may need to thrive in the breath biopsy testing industry. This breath biopsy testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breath biopsy testing market consists of revenues earned by entities by providing services such as metabolic disorder screening, gastrointestinal health assessment, predictive screening and non-invasive testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The breath biopsy testing market also includes sales of breath collection devices, diagnostic software, portable breath testers and wearable breath sensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.